Last reviewed · How we verify

Efalizumab (Raptiva) — Competitive Intelligence Brief

Efalizumab (Raptiva) (Efalizumab (Raptiva)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody (anti-CD11a). Area: Immunology/Dermatology.

marketed Monoclonal antibody (anti-CD11a) CD11a (LFA-1 alpha subunit) Immunology/Dermatology Biologic Live · refreshed every 30 min

Target snapshot

Efalizumab (Raptiva) (Efalizumab (Raptiva)) — Merck KGaA, Darmstadt, Germany. Efalizumab is a monoclonal antibody that blocks CD11a on T cells, preventing their activation and migration to the skin.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Efalizumab (Raptiva) TARGET Efalizumab (Raptiva) Merck KGaA, Darmstadt, Germany marketed Monoclonal antibody (anti-CD11a) CD11a (LFA-1 alpha subunit)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody (anti-CD11a) class)

  1. Merck KGaA, Darmstadt, Germany · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Efalizumab (Raptiva) — Competitive Intelligence Brief. https://druglandscape.com/ci/efalizumab-raptiva. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: